Movement & joint health
The practical interest is comfortable movement, from everyday walking to staying active as we age.
Explore the research →CARTILAGE & CELLULAR AGEING RESEARCH
Cartalax
A small peptide with a growing research story around cartilage cells, tissue maintenance and healthy movement. Also known as AED, Ala-Glu-Asp or T-31, Cartalax is being explored mainly in laboratory studies.
Cartilage cellsJoint-health researchCellular ageing
Interesting cell research; benefits in people remain unestablishedStudies examine how cells behave in the laboratory. They have not established that Cartalax relieves joint pain, regrows cartilage or provides a safe treatment schedule in people.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Cartalax?
Stairs, a longer walk or getting back to a favourite activity can make joint health feel very practical. Cartalax attracts interest because researchers are studying the cells involved in maintaining cartilage and other tissues. The opportunity is worth exploring, while keeping laboratory findings separate from changes someone might notice in daily life.
Cartilage-cell maintenance
Cartilage cells help look after the cushioning tissue inside a joint. Researchers are investigating how AED affects their ageing-related behaviour.
Explore the research →Cellular ageing
Scientists are exploring whether a very short peptide can influence signals that change as cells age.
Explore the research →Tissue-remodelling signals
A related research question concerns the balance between cell renewal and the breakdown of the surrounding tissue framework.
Explore the research →THE SCIENCE BIT
Three building blocks. A question about how cells age.
Cartalax is made from just three amino acids: alanine, glutamic acid and aspartic acid. Their short forms are Ala-Glu-Asp, or AED. You may also see the research name T-31.
Cartilage cells help maintain a joint's cushioning tissue. As cells age, the messages they release and the proteins they make can change. Scientists have exposed cells to AED to investigate some of those changes.
The studies measure cell behaviour and gene activity. They do not yet provide a proven joint-repair mechanism, a validated receptor target or evidence that taking Cartalax reproduces the laboratory findings.
See the studies & trials →- AED sequence
- Three amino-acid building blocks
- Cell signals
- Ageing and inflammation markers
- Gene activity
- Studied in cell cultures
How this connects to the research
The central distinction is between experiments using human cells and trials treating people. The research linked here does not establish joint-pain relief or cartilage regrowth in patients.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Cartalax connects with the body
These are the tissues and biological systems behind the interest in Cartalax.
- Cartilage cells
- Ageing-related signals in laboratory cultures.
- Stem cells
- Human-cell gene-expression experiments.
- Skin fibroblasts
- Preclinical tissue-remodelling research.
The research behind the interest
Movement & joint health
The practical interest is comfortable movement, from everyday walking to staying active as we age.
Cartilage-cell research gives this interest a biological starting point. The linked studies do not establish improvements in pain, stiffness, mobility or exercise recovery in people.
Clinical benefit not establishedExplore the studies →Cartilage-cell maintenance
Cartilage cells help look after the cushioning tissue inside a joint. Researchers are investigating how AED affects their ageing-related behaviour.
A 2023 cell study reported changes in inflammatory and ageing-associated proteins after AED exposure. These are cellular measurements, rather than evidence that damaged cartilage has regrown in a patient.
Laboratory cartilage-cell researchExplore the studies →Cellular ageing
Scientists are exploring whether a very short peptide can influence signals that change as cells age.
A 2020 study found altered expression of genes including IGF1 and NF-kappaB in cultured human stem cells exposed to AED. Human cells in a dish are preclinical evidence, rather than a human treatment trial.
Human-cell laboratory studyExplore the studies →Tissue-remodelling signals
A related research question concerns the balance between cell renewal and the breakdown of the surrounding tissue framework.
A 2016 study of ageing rat skin fibroblasts examined cell renewal, cell-death and matrix-remodelling markers. Its findings should not be treated as proof of a skin, tendon or joint treatment.
Preclinical fibroblast researchExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableAED and ageing-related signals in cartilage cells ↗
Cultured chondrocytes, the cells that maintain cartilage
Applied to cells in culture
Researchers reported changes in inflammatory and ageing-associated proteins, including TNF-alpha, IL-1alpha and Sirt1, after AED exposure.
The study compared AED with a separate cartilage polypeptide complex. It did not measure pain relief, mobility or cartilage regrowth in treated patients.
Short peptides and gene expression in ageing human stem-cell cultures ↗
Human embryonic bone-marrow mesenchymal stem cells, studied in two cell-ageing models
Applied to cells in culture
AED was studied alongside the distinct peptides KED and KE. The researchers reported changes in genes involved in cellular regulation, including IGF1 and NF-kappaB.
Results depended on the peptide and cell model. They do not establish longer life, joint recovery or a safe Cartalax dose in people.
AED and cell-renewal signals in ageing skin fibroblasts ↗
Rat skin fibroblasts aged in culture
Applied to cells in culture
The peptide panel reduced MMP-9 and increased Ki-67 and CD98hc; AED and AEDG also reduced a caspase-dependent cell-death signal.
AED and AEDG are different peptides. Findings in rat skin cells cannot establish a clinical joint or skin benefit from Cartalax.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
Some studies use human cells, but the linked primary studies are laboratory experiments rather than trials treating people.
✓
Clinical efficacyEarly
1/5 evidence depth
A reliable benefit for joint pain, mobility, osteoarthritis or cartilage regrowth has not been established by the studies represented here.
◇
Safety evidenceEarly
1/5 evidence depth
These experiments do not establish adverse-effect rates, interactions, a safe route or long-term safety in people.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Published cartilage-cell, stem-cell and fibroblast studies provide a research rationale, with a limited evidence base and no established clinical translation.
HOW TO READ THESE SCORESDeveloping preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Cartalax research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Cartilage cells
RESEARCH AREA 02Joint-health research
RESEARCH AREA 03Cellular ageing
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Cartalax
The goals behind interest in Cartalax are familiar: easier movement, resilient joints and remaining active with age. This section explores those motivations and the evidence behind them, without presenting personal accounts as proof of a treatment effect.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Everyday movement that feels easier
For someone thinking about joint health, the goal might be a comfortable walk, easier stairs or getting moving after a spell of sitting. These are useful questions for clinical research.
- What makes a report informative
- Walking distance, stiffness and ability to complete ordinary activities over time.
- What can muddy the picture
- Symptoms can change with activity, sleep, pain relief and the natural course of a joint problem.
Returning to a favourite activity
Interest in tissue maintenance often comes from wanting to keep exercising, working or enjoying hobbies. A meaningful outcome would include sustained function during ordinary activity.
- What makes a report informative
- A lasting return to a specific activity, with its usual level of effort recorded.
- What can muddy the picture
- Rehabilitation, changes in training load and other treatments can all influence recovery.
Looking after joints as we age
Cartalax's cell-ageing research raises questions about maintaining cartilage over time. Answering them requires clinical studies with measurements that go beyond how a joint feels.
- What makes a report informative
- Clinical function and, where appropriate, direct structural assessment with suitable follow-up.
- What can muddy the picture
- Reduced discomfort does not by itself demonstrate preserved or regenerated cartilage.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
More comfortable everyday movement
Walking, stairs and getting up after sitting are meaningful outcomes for someone interested in joint health.
Human findings & limits
The linked studies do not establish an improvement in pain or function in people receiving Cartalax.
Laboratory & animal context
Cartilage-cell experiments examine ageing-related inflammatory signals.
What this means: A useful goal for future trials, with clinical benefit still to be demonstrated.
Maintaining cartilage over time
Interest often centres on looking after the joint itself, alongside how it feels.
Human findings & limits
Cartilage preservation or regrowth would need direct clinical measurements and suitable follow-up.
Laboratory & animal context
Cellular changes provide a starting point for research into tissue maintenance.
What this means: Feeling better and having demonstrably healthier cartilage are separate outcomes.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
An evidence-based human dose, route, frequency and course length for Cartalax have not been established by the studies on this page. Concentrations applied to cells in a dish cannot be converted into an injection or oral schedule.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
The human safety picture still needs to be established
What the current evidence saysThe linked cell studies cannot tell us how often side effects occur in people, which medicines might interact with Cartalax or whether repeated exposure is safe. Product identity, impurities and sterility introduce separate questions. A certificate of analysis can help describe a batch, but it cannot establish clinical safety or effectiveness.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
7 sourcesSources used on this profile
Primary researchAED and ageing-related signals in cartilage cellsOriginal study record · Myakisheva et al., 2023 ↗Primary researchShort peptides and gene expression in ageing human stem-cell culturesOriginal study record · Ashapkin et al., 2020 ↗Original publicationShort peptides and gene expression in ageing human stem-cell culturesJournal / DOI ↗Primary researchAED and cell-renewal signals in ageing skin fibroblastsOriginal study record · Lin'kova et al., 2016 ↗Original publicationAED and cell-renewal signals in ageing skin fibroblastsJournal / DOI ↗Professional sourceIdentity & namingT-31 (AED) in the research literature ↗Professional sourceChemical recordEMBL-EBI ChEBI chemical record ↗
CURRENT STATUS
How to interpret its position today
Experimental peptide; clinical outcomes unestablished
The studies represented here are preclinical. Published cell findings do not establish an authorised medicine, an effective treatment or a consumer dosing schedule.
Primary cartilage-cell study ↗Cartalax · AED · Ala-Glu-Asp · T-31
AED is the three-amino-acid sequence alanine, glutamic acid and aspartic acid. T-31 is a research designation. Epitalon (AEDG) and cartilage peptide mixtures are different materials, so their evidence should be assessed separately.
T-31 (AED) in the research literature ↗A three-amino-acid peptide
The Ala-Glu-Asp chemical entry records a tripeptide with a molecular mass of approximately 333.3 g/mol. The trade name alone cannot verify the identity of a supplied product.
EMBL-EBI ChEBI chemical record ↗Profile reviewed against its linked source record on 17 October 2026. See how evidence is assessed.